Home › Funds › Boxer Capital Management, LLC › PTGX

Boxer Capital Management, LLC position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

Boxer Capital Management, LLC reported holding 170,000 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$20.8M, representing 1.57% of its reported portfolio and ranking #15 among its reported holdings. Boxer Capital Management, LLC has disclosed PTGX holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)170.00K sh
Reported value held$20.84M
Portfolio Weight1.57%
First reportedQ2 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Boxer Capital Management, LLC's PTGX position evolved

Boxer Capital Management, LLC first disclosed a stake in PTGX in Q2 2025 at 60,000 shares (US$3.3M). The position peaked in Q2 2026 at 170,000 shares, worth US$20.8M. Across 5 filings, Boxer Capital Management, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 170,000 shares valued at US$20.8M. Notable position changes include a 83% increase in Q3 2025 (shares rose 31% over the following quarter), a 55% increase in Q4 2025 (shares rose 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 60.00K $3.32M New
Q3 2025 110.00K $7.31M Add
Q4 2025 170.00K $14.85M Add
Q1 2026 170.00K $17.92M Hold
Q2 2026 170.00K $20.84M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has Boxer Capital Management, LLC held PTGX?

Boxer Capital Management, LLC has disclosed PTGX holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Boxer Capital Management, LLC's current position in PTGX?

As of Q2 2026, Boxer Capital Management, LLC holds 170.00K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $20.84M, representing 1.57% of its reported portfolio and ranking #15.

Has Boxer Capital Management, LLC been buying or selling PTGX?

In the latest 13F filing (Q2 2026), Boxer Capital Management, LLC held unchanged its position in PTGX. The position peaked in Q2 2026 at 170.00K shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.